Exchange: NYSE
Industry: Drug Manufacturers/Other
Last Trade: 4:01 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.00 | 0.88 | 13.64 |
| EPS, GAAP | 0.90 | 0.87 | 3.45 |
| Consensus Estimate | 1.00 | 0.89 | 12.36 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.65 | 3.65 | 0.00 |
| EPS, GAAP | 2.98 | -0.01 | NA |
| Consensus Estimate | 3.59 | NA | NA |
| AGN | Industry Average | |
| P/E (TTM) | 29.32 | 29.30 |
| P/E (Forward) | 20.90 | 13.00 |
| PEG Ratio | 1.49 | 2.50 |
| Price/Sales | 5.08 | 4.56 |
| Beta | 0.82 | 0.57 |
| 11:59 AM | 2/2/2012 | UPDATE: Allergan 4Q Net Rises 6.3% On Eye Care Sales |
| 11:28 AM | 2/2/2012 | CORRECT: Allergan 4Q Net Rose 6.3%, Margins Improve; R&D Costs Higher |
| 1/31/2012 | Tomorrow's Tape: ADP, ISM And Plenty Of EPS (WSJ.com) |
| 1/6/2012 | Tech Fund Thinks Outside Of Box; Managers Favor MON, AGN, ILMN (Barrons.com) |
| 12/31/2011 | S&P 500 Companies' Fourth-Quarter Earnings Guidance (Barrons.com) |
| 12/16/2011 | Valeant Sets Its Sights on Another Takeover Target (WSJ.com) |
| 12/14/2011 | A.M. Vitals: Merck CEO Defends R&D Investment (WSJ.com) |
| 12/9/2011 | Don't just ask, "How much inventory?" Ask, "What kind?" (The Motley Fool) |
| 12/1/2011 | Top Analyst Upgrades & Downgrades (AGN, CRZO, XRAY, DWA, ERTS, IAG, GOOG, LLTC, ONXX, STX, SIG, VRSN, YHOO, DGI, GEOY) (24/7 Wall St) |
| 11/23/2011 | Stock Charts Point to Near-Term Risk, Rewards Later (Barrons.com) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
